News & Media

ARMS Medical announces 300 “no-mesh” pelvic floor procedures by U.S. surgeons using novel allograft to avoid complications

ARMS Medical and Tissue Regenix BioSurgery sign exclusive distributor agreement for DermaPure® allograft with dCELL® technology

ARMS inks 5-year exclusive partnership for DermaPure®

ARMS Medical/Tissue Regenix to exhibit at SUFU 2018 regional meeting

AUGS publishes best practice statement on pelvic organ prolapse

DermaPure demonstrates significant cost savings and clinical benefits to healthcare providers

FDA orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices

FDA reclassifies vaginal mesh, device used for prolapse, as ‘high risk’

FDA strengthens requirements for surgical mesh for the transvaginal repair of pelvic organ prolapse to address safety risks

Mesh News highlights for 2017 revisited

NHS England puts an immediate curb on mesh operations after safety concerns

Surgical smoke nearly killed me

Tissue Regenix completes technical transfer of DermaPure® manufacturing at CellRight facility in San Antonio, Texas

Tissue Regenix launches new unit as it inks US distribution deal

Tissue Regenix rings changes after Cellright acquisition

What to know about pelvic organ prolapse